125 related articles for article (PubMed ID: 20849835)
1. Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3.
Yamamoto-Watanabe Y; Watanabe M; Jackson M; Akimoto H; Sugimoto K; Yasujima M; Wakasaya Y; Matsubara E; Kawarabayashi T; Harigaya Y; Lyndon AR; Shoji M
Brain Res; 2010 Nov; 1361():140-5. PubMed ID: 20849835
[TBL] [Abstract][Full Text] [Related]
2. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
3. The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease.
Maetzler W; Schmid B; Synofzik M; Schulte C; Riester K; Huber H; Brockmann K; Gasser T; Berg D; Melms A
J Alzheimers Dis; 2010; 19(3):937-42. PubMed ID: 20157249
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of the cystatin C(CST3) gene G73A polymorphism and susceptibility to Alzheimer's disease.
Hua Y; Zhao H; Lu X; Kong Y; Jin H
Int J Neurosci; 2012 Aug; 122(8):431-8. PubMed ID: 22435454
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus antibodies in serum and cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy and amyotrophic lateral sclerosis.
Nociti V; Frisullo G; Marti A; Luigetti M; Iorio R; Patanella AK; Bianco A; Tonali PA; Grillo RL; Sabatelli M; Batocchi AP
J Neuroimmunol; 2010 Aug; 225(1-2):149-52. PubMed ID: 20510468
[TBL] [Abstract][Full Text] [Related]
6. Flanking markers of cystatin c (CST3) gene do not show association with Alzheimer's disease.
Helisalmi S; Väkevä A; Hiltunen M; Soininen H
Dement Geriatr Cogn Disord; 2009; 27(4):318-21. PubMed ID: 19293566
[TBL] [Abstract][Full Text] [Related]
7. Cystatin C in cerebrospinal fluid as a biomarker of ALS.
Tsuji-Akimoto S; Yabe I; Niino M; Kikuchi S; Sasaki H
Neurosci Lett; 2009 Mar; 452(1):52-5. PubMed ID: 19444952
[TBL] [Abstract][Full Text] [Related]
8. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders.
Meyne F; Gloeckner SF; Ciesielczyk B; Heinemann U; Krasnianski A; Meissner B; Zerr I
J Alzheimers Dis; 2009; 17(4):863-73. PubMed ID: 19542614
[TBL] [Abstract][Full Text] [Related]
9. Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease.
Chuo LJ; Sheu WH; Pai MC; Kuo YM
Dement Geriatr Cogn Disord; 2007; 23(4):251-7. PubMed ID: 17310123
[TBL] [Abstract][Full Text] [Related]
10. Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer's disease, Parkinson's disease, and multiple system atrophy.
Nishimura M; Kuno S; Kaji R; Kawakami H
Mov Disord; 2005 Aug; 20(8):1031-3. PubMed ID: 15838855
[TBL] [Abstract][Full Text] [Related]
11. Contribution of cystatin C gene polymorphisms to cerebral white matter lesions.
Mitaki S; Nagai A; Sheikh AM; Terashima M; Isomura M; Nabika T; Yamaguchi S
Cerebrovasc Dis; 2011; 32(5):489-96. PubMed ID: 22057131
[TBL] [Abstract][Full Text] [Related]
12. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
13. [Leukotrienes and neurological diseases].
Irkeç C; Ercan S; Irkeç M
Mikrobiyol Bul; 1989 Oct; 23(4):342-7. PubMed ID: 2488942
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid levels of free 3-nitrotyrosine are not elevated in the majority of patients with amyotrophic lateral sclerosis or Alzheimer's disease.
Ryberg H; Söderling AS; Davidsson P; Blennow K; Caidahl K; Persson LI
Neurochem Int; 2004 Jul; 45(1):57-62. PubMed ID: 15082222
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
Holmberg B; Johnels B; Blennow K; Rosengren L
Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
[TBL] [Abstract][Full Text] [Related]
16. Decreased chloride levels of cerebrospinal fluid in patients with amyotrophic lateral sclerosis.
Watanabe S; Kimura T; Suenaga K; Wada S; Tsuda K; Kasama S; Takaoka T; Kajiyama K; Takeda M; Yoshikawa H
J Neurol Sci; 2009 Oct; 285(1-2):146-8. PubMed ID: 19595376
[TBL] [Abstract][Full Text] [Related]
17. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.
Hansson SF; Andréasson U; Wall M; Skoog I; Andreasen N; Wallin A; Zetterberg H; Blennow K
J Alzheimers Dis; 2009; 16(2):389-97. PubMed ID: 19221428
[TBL] [Abstract][Full Text] [Related]
18. Patterns of levels of biological metals in CSF differ among neurodegenerative diseases.
Hozumi I; Hasegawa T; Honda A; Ozawa K; Hayashi Y; Hashimoto K; Yamada M; Koumura A; Sakurai T; Kimura A; Tanaka Y; Satoh M; Inuzuka T
J Neurol Sci; 2011 Apr; 303(1-2):95-9. PubMed ID: 21292280
[TBL] [Abstract][Full Text] [Related]
19. Genetic analysis of the cystatin C gene in familial and sporadic ALS patients.
Watanabe M; Jackson M; Ikeda M; Mizushima K; Amari M; Takatama M; Hirai S; Ikeda Y; Shizuka-Ikeda M; Okamoto K
Brain Res; 2006 Feb; 1073-1074():20-4. PubMed ID: 16443201
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-β1 in the cerebrospinal fluid of patients with distinct neurodegenerative diseases.
Masuda T; Itoh J; Koide T; Tomidokoro Y; Takei Y; Ishii K; Tamaoka A
J Clin Neurosci; 2017 Jan; 35():47-49. PubMed ID: 27756506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
